While LDH-A inhibitors have been shown to improve gemcitabine sensitivity in PDAC cell lines, implicating LDH-A as a biomarker of resistance13, in general, there is a lack of specific and sensitive preclinical prognostic markers indicative of tumor responsiveness or resistance to treatment14. Here, LDHA is linked to neoplasm.